Sunday, 14 August 2022



LATEST NEWS Har Ghar Tiranga: District Administration Shopian organises Mega Tiranga Rally Mission Amrit Sarovar: DDC Anantnag inaugurates ponds at Qulam Chinar & Badasgam DC Budgam Shahbaz Ahmed Mirza flags-off ‘Har Ghar Tiranga’ rally of Specially-abled persons DDC Chairperson Ganderbal unfurls tricolor at DDC Office 16 new medical colleges to be set up in Punjab: Bhagwant Mann Mission AABAD 30 : A Unique Initiative Launched for the Overall Development of 30 Border Villages of Fazilka Thousands participate in Congress Tiranga Yatra in Gidderbaha, Mansa 75th Mahautsav of Independence was started by hoisting the Tricolor by the Department of Tourism and Culture Vigilance Bureau nabs 8 officials in 5 different bribery cases during July Amit Kapoor conducted door to door campaign in Khairi village of Bishnah Australian legend Ian Chappell calls time on his career inside the commentary box Since 1917, Jharkhand's Tana Bhagats have been worshipping the Tricolour daily One thing that stands out is how Rohit Sharma backs players who aren't performing: Parthiv Patel Since 1917, Jharkhand's Tana Bhagats have been worshipping the Tricolour daily This drug can fight more than 300 drug-resistant bacteria Madonna Sebastian to appear opposite Tovino Thomas in 'Identity' Australia plans to increase migrant intake amid skill crisis A Rajasthan Royals owner slapped me three or four times, says Ross Taylor in his autobiography PM pays homage to all those who lost their lives during Partition Saumya Tandon urges fans to help late 'Bhabiji' star Deepesh Bhan's family repay loan No Olympic future for CWG lawn bowls 'trailblazers', squash players


Omicron-targeting Covid vax shows high immune response: Pfizer & BioNTech

Omicron Variant, Delta Plus Covid variant, Delta Covid-19 variant, Coronavirus, COVID 19, Novel Coronavirus, Fight Against Corona, Covaxin, Covishield, Covid-19 Vaccine, Oxygen, Oxygen Cylinders, SARS-CoV-2, Sputnik V, Oxygen Plants, Pfizer, Astra Zeneca, Oxygen Concentrator, Remdesivir, Covifor, Oximeter

Web Admin

Web Admin

5 Dariya News

New York , 26 Jun 2022

The new Covid shot that specifically targets Omicron variant elicits a strong immune response against the strain, widely known to evade vaccines, Pfizer and BioNTech have said.

According to the companies, just a month after administration, a booster dose of the Omicron-adapted monovalent candidates (at 30 and 60 microgram doses) increased neutralising antibodies against Omicron BA.1 to 13.5 and 19.6-fold above pre-booster dose levels.

A booster dose of the Omicron-adapted bivalent candidates conferred a 9.1 and 10.9-fold increase in neutralising antibodies against Omicron BA.1, that was circulating last winter.

Data from the Phase 2/3 trial that included 1,234 people aged 56 or older, showed that both Omicron-adapted vaccine candidates were well-tolerated in participants, the companies said.

"Based on these data, we believe we have two very strong Omicron-adapted candidates that elicit a substantially higher immune response against Omicron than we've seen to date," said Albert Bourla, Chairman and Chief Executive Officer, Pfizer, in a statement.

"Omicron has newly evolving sublineages that have outcompeted BA.1 and exhibit a trend of increasing potential for immune escape. We will therefore remain vigilant and are prepared to rapidly adapt our Omicron-adapted vaccine candidates to emerging sublineages if epidemiological and laboratory data suggest, added Prof. Ugur Sahin, CEO and Co-founder of BioNTech.

Further, the companies noted that their early laboratory studies suggest that both Omicron-modified candidates also neutralise the Omicron BA.4 and BA.5 sub-variants that have been circulating more recently, with approximately 3-fold lower antibodies than BA.1.

The companies stated they are continuing to collect data on how well the boosters perform versus the more recently circulating strains.The companies will share the results with the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), ahead of the FDA advisory committee meeting on June 28, to discuss whether to update Covid vaccines.

The companies have also submitted additional data from their ongoing Covid-19 booster studies, including data on an additional dose of their current Covid-19 vaccine and Beta candidate, to further demonstrate the flexibility and potential benefit of mRNA-based vaccines.

Meanwhile, rival Moderna has also made a redesigned vaccine targeting the BA.1 Omicron subvariant. The company said its updated vaccine worked well against more recent Omicron subvariants, and that it was moving forward with plans to ask regulators for approval.


Tags: Omicron Variant , Delta Plus Covid variant , Delta Covid-19 variant , Coronavirus , COVID 19 , Novel Coronavirus , Fight Against Corona , Covaxin , Covishield , Covid-19 Vaccine , Oxygen , Oxygen Cylinders , SARS-CoV-2 , Sputnik V , Oxygen Plants , Pfizer , Astra Zeneca , Oxygen Concentrator , Remdesivir , Covifor , Oximeter



related news




Photo Gallery



Video Gallery



5 Dariya News RNI Code: PUNMUL/2011/49000
© 2011-2022 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD